July 6, 2018

Please reload

Recent Posts

FDA Comments on Recently Released Rare Disease Guidance for Industry

September 16, 2015

Jonathan Goldsmith, M.D., F.A.C.P., FDA’s Associate Director, Rare Diseases Program, Center for Drug Evaluation and Research, comments on the recently...

Please reload

Featured Posts

Patagonia Completes Phase 2a Clinical Study for PAT-001

February 13, 2018

Patagonia is excited to announce the completion of our Phase 2a clinical study for PAT-001.  This proof-of-concept study was conducted at 5 sites throughout the United States and investigated the potential of PAT-001 in Congenital Ichthyosis. 


Ichthyosis is a family of genetic skin disorders characterized by dry, scaling skin that may be thickened or very thin. This condition affects people of all ages, races and gender. The disease usually presents at birth, or within the first year, and will continue to affect the patient throughout their lifetime.¹


We would like to thank our investigators and the team at FIRST (http://www.firstskinfoundation.org/) for their support throughout this study.


If you are interested in participating in a future study, please visit the following link: www.ichthyosistrial.com


If you are an investigator interested in participating in a future study, please contact info@patagoniarx.com





Please reload

Patagonia Pharmaceuticals, LLC

50 Tice Blvd, Suite A26

Woodcliff Lake, NJ 07677

For more info: info@patagoniarx.com

© 2019 by Patagonia Pharmaceuticals, LLC